Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

547.36 -0.38 (-0.07%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Why Regeneron Is Falling And Why You Should Avoid It
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN. 
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce. 
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500
Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the... 
Via Stocktwits
Topics Death
Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For May 30
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN)
US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty. 
Via Chartmill
Topics World Trade
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts. 
Via Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Top S&P500 movers in Friday's session
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic... 
Via StockStory
Topics Artificial Intelligence
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Unity Stock Jumps On Upgrade While Regeneron, Cooper Companies Tank On Downgrades – Top Wall Street Analyst Calls Today
Jefferies upgraded Unity’s stock to ‘Buy’ from ‘Hold’ with a price target hike to $29 from $22. 
Via Stocktwits
Topics ETFs Economy Stocks
Friday's session: gap up and gap down stock in the S&P500 index
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends. 
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session. 
Via Chartmill
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal. 
Via Benzinga
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes. 
Via Stocktwits
Topics Government Stocks
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.